Not recruitingISRCTN02457313
Effectiveness of support groups in Schizophrenia
This study isn't currently recruiting.
In NetherlandsSchizophreniaResearch studyAges 18+
Schizophrenia studies
Schizophrenia
Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.
Not recruitingISRCTN17220814
The efficacy of cognitive remediation on processing speed in people with first episode psychosis
This study isn't currently recruiting.
In MalaysiaSchizophreniaResearch studyAges 18+
Not recruitingISRCTN14087654
The feasibility and implementation of the Psychosis Risk Prediction Algorithm
This study isn't currently recruiting.
In United KingdomSchizophreniaResearch studyAges 18–80
Not recruitingISRCTN73188383
The GOALS study: evaluation of a brief cognitive-behavioural therapy (CBT) treatment to support people with psychosis to reach personal goals
This study isn't currently recruiting.
In United KingdomSchizophreniaResearch studyAges 18+
Not recruitingISRCTN12424842
Vitamin D supplementation compared to placebo in people presenting with their first episode of psychosis neuroprotection design
This study isn't currently recruiting.
In United KingdomSchizophreniaResearch studyAges 18–65
Recruitment unclearEUCTR 2004-004281-32
“Double blind, placebo-controlled study of efficacy, safety and tolerance of raloxifene as an adjuvant treatment for negative symptoms of schizophrenia in postmenopausal women” Estudio doble ciego...
Current recruitment status is unconfirmed.
This older record does not confirm current recruitment. No matching public CTIS record was confirmed using this identifier. Ask the research team for an up-to-date source.
In SpainSchizophreniaHistorical research record
Recruitment unclearEUCTR 2016-003435-38
A 52-Week, Open-Label, Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia
Current recruitment status is unconfirmed.
This older record does not confirm current recruitment. No matching public CTIS record was confirmed using this identifier. Ask the research team for an up-to-date source.
In BulgariaSchizophreniaHistorical research record
Recruitment unclearEUCTR 2007-007538-21
A Multi-center, Inpatient and ambulatory, Phase 2, Double-blind, Randomised, Placebo-controlled Proof of Concept Study of CYR-101 in Patients with DSM-IV Schizophrenia
Current recruitment status is unconfirmed.
This older record does not confirm current recruitment. No matching public CTIS record was confirmed using this identifier. Ask the research team for an up-to-date source.
In FranceSchizophreniaHistorical research record
Recruitment unclearEUCTR 2019-003343-29
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE 2)
Current recruitment status is unconfirmed.
This older record does not confirm current recruitment. No matching public CTIS record was confirmed using this identifier. Ask the research team for an up-to-date source.
In BulgariaSchizophreniaHistorical research record
Recruitment unclearEUCTR 2019-002259-40
A Randomized, Double-blind, Active Comparator-Controlled Study to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Subjects with Schizophrenia
Current recruitment status is unconfirmed.
This older record does not confirm current recruitment. No matching public CTIS record was confirmed using this identifier. Ask the research team for an up-to-date source.
In RomaniaSchizophreniaHistorical research record
Recruitment unclearEUCTR 2009-011594-33
A randomized, double-blind, placebo-controlled study of tetrabenazine as adjunctive therapy to risperidone in first-episode schizophrenia
Current recruitment status is unconfirmed.
This older record does not confirm current recruitment. No matching public CTIS record was confirmed using this identifier. Ask the research team for an up-to-date source.
In GermanySchizophreniaHistorical research record
Recruitment unclearEUCTR 2008-001015-38
A randomized, placebo-controlled study of the central cannabinoid (CB1) receptor antagonist rimonabant as adjunctive therapy to improve cognition in schizophrenia
Current recruitment status is unconfirmed.
This older record does not confirm current recruitment. No matching public CTIS record was confirmed using this identifier. Ask the research team for an up-to-date source.
In GermanySchizophreniaHistorical research record
Registry coverage
We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.